Lindera obtusiloba Blume Alleviates Non-Alcoholic Fatty Liver Disease Promoted by Nε-(carboxymethyl)lysine
Abstract
:1. Introduction
2. Materials and Methods
2.1. Preparation of LO Extract
2.2. Identification of LO Extract Marker Compound by High-Performance Liquid Chromatography (HPLC)
2.3. Determination of Anti-Glycation
2.4. Cell Culture and Treatment
2.5. Assessment of Cell Viability
2.6. Measurement of Intracellular Nε-(carboxymethyl)lysine (CML)
2.7. ORO Staining for Hepatocyte
2.8. Animals
2.9. Biochemical Analysis
2.10. Histology and Immunohistochemistry
2.11. Western Blotting
2.12. Statistical Analysis
3. Results
3.1. HPLC Analysis of LO Extract
3.2. Effect of LO on Anti-Glycation
3.3. Effect of LO on Anti-Glycation and Inhibition of Lipid Accumulation in AML-12 Cells
3.4. Effect of LO on Body Weight and Serum Biochemical Markers in Mice
3.5. Effect of LO on Histological Parameter in Liver Tissue
3.6. Effect of LO on Hepatic De Novo Lipogenesis (DNL)
3.7. Effect of LO on MAPK/NF-κB Regulation
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Paik, J.M.; Henry, L.; Younossi, Y.; Ong, J.; Alqahtani, S.; Younossi, M. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. Hepatol. Commun. 2023, 7, e0251. [Google Scholar] [CrossRef] [PubMed]
- Chalasani, N.; Younossi, Z.; Lavine, J.E.; Diehl, A.M.; Brunt, E.M.; Cusi, K.; Charlton, M.; Sanyal, A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012, 142, 1592–1609. [Google Scholar] [CrossRef] [PubMed]
- Hydes, T.; Alam, U.; Cuthbertson, D.J. The Impact of Macronutrient Intake on Non-alcoholic Fatty Liver Disease (NAFLD): Too Much Fat, Too Much Carbohydrate, or Just Too Many Calories? Front. Nutr. 2021, 8, 640557. [Google Scholar] [CrossRef] [PubMed]
- Steele, E.M.; Batis, C.; Cediel, G.; Louzada, M.L.d.C.; Khandpur, N.; Machado, P.; Moubarac, J.-C.; Rauber, F.; Jedlicki, M.R.; Levy, R.B.; et al. The burden of excessive saturated fatty acid intake attributed to ultra-processed food consumption: A study conducted with nationally representative cross-sectional studies from eight countries. J. Nutr. Sci. 2021, 10, e43. [Google Scholar] [CrossRef] [PubMed]
- Vistoli, G.; De Maddis, D.; Cipak, A.; Zarkovic, N.; Carini, M.; Aldini, G. Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): An overview of their mechanisms of formation. Free Radic. Res. 2013, 47 (Suppl. 1), 3–27. [Google Scholar] [CrossRef] [PubMed]
- Singh, S.; Siva, B.V.; Ravichandiran, V. Advanced Glycation End Products: Key player of the pathogenesis of atherosclerosis. Glycoconj. J. 2022, 39, 547–563. [Google Scholar] [CrossRef]
- Tan, K.C.; Chow, W.S.; Ai, V.H.; Metz, C.; Bucala, R.; Lam, K.S. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 2002, 25, 1055–1059. [Google Scholar] [CrossRef]
- Gaens, K.H.; Stehouwer, C.D.; Schalkwijk, C.G. Advanced glycation endproducts and its receptor for advanced glycation endproducts in obesity. Curr. Opin. Lipidol. 2013, 24, 4–11. [Google Scholar] [CrossRef] [PubMed]
- Ahmad, S.; Khan, H.; Siddiqui, Z.; Khan, M.Y.; Rehman, S.; Shahab, U.; Godovikova, T.; Silnikov, V. AGEs, RAGEs and s-RAGE; friend or foe for cancer. Semin. Cancer Biol. 2018, 49, 44–55. [Google Scholar] [CrossRef]
- Thornalley, P.J. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch. Biochem. Biophys. 2003, 419, 31–40. [Google Scholar] [CrossRef]
- Voziyan, P.A.; Hudson, B.G. Pyridoxamine: The many virtues of a maillard reaction inhibitor. Ann. N. Y. Acad. Sci. 2005, 1043, 807–816. [Google Scholar] [CrossRef]
- Engelen, L.; Stehouwer, C.D.; Schalkwijk, C.G. Current therapeutic interventions in the glycation pathway: Evidence from clinical studies. Diabetes Obes. Metab. 2013, 15, 677–689. [Google Scholar] [CrossRef]
- Khan, M.; Liu, H.; Wang, J.; Sun, B. Inhibitory effect of phenolic compounds and plant extracts on the formation of advance glycation end products: A comprehensive review. Food Res. Int. 2020, 130, 108933. [Google Scholar] [CrossRef]
- Wang, J.; Liu, H.; Xie, G.; Cai, W.; Xu, J. Identification of hub genes and key pathways of dietary advanced glycation end products-induced non-alcoholic fatty liver disease by bioinformatics analysis and animal experiments. Mol. Med. Rep. 2020, 21, 685–694. [Google Scholar] [CrossRef]
- Pang, Q.; Sun, Z.; Shao, C.; Cai, H.; Bao, Z.; Wang, L.; Li, L.; Jing, L.; Zhang, L.; Wang, Z. CML/RAGE Signal Bridges a Common Pathogenesis Between Atherosclerosis and Non-alcoholic Fatty Liver. Front. Med. 2020, 7, 583943. [Google Scholar] [CrossRef]
- Li, Y.; Qin, M.; Zhong, W.; Liu, C.; Deng, G.; Yang, M.; Li, J.; Ye, H.; Shi, H.; Wu, C.; et al. RAGE promotes dysregulation of iron and lipid metabolism in alcoholic liver disease. Redox Biol. 2023, 59, 102559. [Google Scholar] [CrossRef]
- Tan, H.; Hu, J.; Zuo, W.; Huang, Y.; Cui, J.; Gong, F.; Bai, W. Loss of RAGE prevents chronic intermittent hypoxia-induced nonalcoholic fatty liver disease via blockade of NF-κB pathway. Gene Ther. 2023, 30, 278–287. [Google Scholar] [CrossRef]
- Otazu, G.K.; Dayyani, M.; Badie, B. Role of RAGE and Its Ligands on Inflammatory Responses to Brain Tumors. Front. Cell. Neurosci. 2021, 15, 770472. [Google Scholar] [CrossRef]
- Sorci, G.; Riuzzi, F.; Giambanco, I.; Donato, R. RAGE in tissue homeostasis, repair and regeneration. Biochim. Biophys. Acta (BBA)-Mol. Cell Res. 2013, 1833, 101–109. [Google Scholar] [CrossRef]
- Leung, C.; Herath, C.B.; Jia, Z.; Goodwin, M.; Mak, K.Y.; Watt, M.J.; Forbes, J.M.; Angus, P.W. Dietary glycotoxins exacerbate progression of experimental fatty liver disease. J. Hepatol. 2014, 60, 832–838. [Google Scholar] [CrossRef]
- Yook, C. Medicinal Plants of Korea; Academy Publishing Co.: Seoul, Republic of Korea, 1989. [Google Scholar]
- Lee, J.O.; Auger, C.; Park, D.H.; Kang, M.; Oak, M.H.; Kim, K.R.; Schini-Kerth, V.B. An ethanolic extract of Lindera obtusiloba stems, YJP-14, improves endothelial dysfunction, metabolic parameters and physical performance in diabetic db/db mice. PLoS ONE 2013, 8, e65227. [Google Scholar] [CrossRef]
- Freise, C.; Erben, U.; Neuman, U.; Kim, K.; Zeitz, M.; Somasundaram, R.; Ruehl, M. An active extract of Lindera obtusiloba inhibits adipogenesis via sustained Wnt signaling and exerts anti-inflammatory effects in the 3T3-L1 preadipocytes. J. Nutr. Biochem. 2010, 21, 1170–1177. [Google Scholar] [CrossRef] [PubMed]
- Freise, C.; Ruehl, M.; Erben, U.; Neumann, U.; Seehofer, D.; Kim, K.Y.; Trowitzsch-Kienast, W.; Stroh, T.; Zeitz, M.; Somasundaram, R. A hepatoprotective Lindera obtusiloba extract suppresses growth and attenuates insulin like growth factor-1 receptor signaling and NF-kappaB activity in human liver cancer cell lines. BMC Complement. Altern. Med. 2011, 11, 39. [Google Scholar] [CrossRef] [PubMed]
- Ihm, S.H.; Park, S.H.; Lee, J.O.; Kim, O.R.; Park, E.H.; Kim, K.R.; Kim, J.H.; Hwang, B.H.; Youn, H.J.; Oak, M.H.; et al. A Standardized Lindera obtusiloba Extract Improves Endothelial Dysfunction and Attenuates Plaque Development in Hyperlipidemic ApoE-Knockout Mice. Plants 2021, 10, 2493. [Google Scholar] [CrossRef] [PubMed]
- Hong, C.O.; Lee, H.A.; Rhee, C.H.; Choung, S.Y.; Lee, K.W. Separation of the antioxidant compound quercitrin from Lindera obtusiloba Blume and its antimelanogenic effect on B16F10 melanoma cells. Biosci. Biotechnol. Biochem. 2013, 77, 58–64. [Google Scholar] [CrossRef] [PubMed]
- Singh, R.; Barden, A.; Mori, T.; Beilin, L. Advanced glycation end-products: A review. Diabetologia 2001, 44, 129–146. [Google Scholar] [CrossRef] [PubMed]
- Snelson, M.; Coughlan, M.T. Dietary Advanced Glycation End Products: Digestion, Metabolism and Modulation of Gut Microbial Ecology. Nutrients 2019, 11, 215. [Google Scholar] [CrossRef] [PubMed]
- Haque, M.E.; Azam, S.; Balakrishnan, R.; Akther, M.; Kim, I.S. Therapeutic Potential of Lindera obtusiloba: Focus on Antioxidative and Pharmacological Properties. Plants 2020, 9, 1765. [Google Scholar] [CrossRef] [PubMed]
- Yoon, S.-R.; Shim, S.-M. Inhibitory effect of polyphenols in Houttuynia cordata on advanced glycation end-products (AGEs) by trapping methylglyoxal. LWT-Food Sci. Technol. 2015, 61, 158–163. [Google Scholar] [CrossRef]
- Jang, D.S.; Kim, J.M.; Kim, J.; Yoo, J.L.; Kim, Y.S.; Kim, J.S. Effects of compounds isolated from the fruits of Rumex japonicus on the protein glycation. Chem. Biodivers. 2008, 5, 2718–2723. [Google Scholar] [CrossRef]
- Cohen, J.C.; Horton, J.D.; Hobbs, H.H. Human fatty liver disease: Old questions and new insights. Science 2011, 332, 1519–1523. [Google Scholar] [CrossRef] [PubMed]
- Bierhaus, A.; Humpert, P.M.; Morcos, M.; Wendt, T.; Chavakis, T.; Arnold, B.; Stern, D.M.; Nawroth, P.P. Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 2005, 83, 876–886. [Google Scholar] [CrossRef] [PubMed]
- Patel, R.; Baker, S.S.; Liu, W.; Desai, S.; Alkhouri, R.; Kozielski, R.; Mastrandrea, L.; Sarfraz, A.; Cai, W.; Vlassara, H.; et al. Effect of dietary advanced glycation end products on mouse liver. PLoS ONE 2012, 7, e35143. [Google Scholar] [CrossRef]
- Leung, C.; Herath, C.B.; Jia, Z.; Andrikopoulos, S.; Brown, B.E.; Davies, M.J.; Rivera, L.R.; Furness, J.B.; Forbes, J.M.; Angus, P.W. Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease. World J. Gastroenterol. 2016, 22, 8026–8040. [Google Scholar] [CrossRef]
- Litwinowicz, K.; Waszczuk, E.; Gamian, A. Advanced Glycation End-Products in Common Non-Infectious Liver Diseases: Systematic Review and Meta-Analysis. Nutrients 2021, 13, 3370. [Google Scholar] [CrossRef] [PubMed]
- Lee, H.B.; Choi, J.H.; Kim, D.; Lee, K.W.; Ha, S.K.; Lee, S.H.; Park, H.Y. Dietary N(ε)-(carboxymethyl)lysine is a trigger of non-alcoholic fatty liver disease under high-fat consumption. Food Chem. Toxicol. 2023, 180, 114010. [Google Scholar] [CrossRef] [PubMed]
- Xu, X.; So, J.S.; Park, J.G.; Lee, A.H. Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin. Liver Dis. 2013, 33, 301–311. [Google Scholar] [CrossRef] [PubMed]
- Browning, J.D.; Horton, J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Investig. 2004, 114, 147–152. [Google Scholar] [CrossRef]
- Iizuka, K.; Bruick, R.K.; Liang, G.; Horton, J.D.; Uyeda, K. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc. Natl. Acad. Sci. USA 2004, 101, 7281–7286. [Google Scholar] [CrossRef]
- Diehl, A.M.; Li, Z.P.; Lin, H.Z.; Yang, S.Q. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005, 54, 303–306. [Google Scholar] [CrossRef]
- Gaens, K.H.; Niessen, P.M.; Rensen, S.S.; Buurman, W.A.; Greve, J.W.; Driessen, A.; Wolfs, M.G.; Hofker, M.H.; Bloemen, J.G.; Dejong, C.H.; et al. Endogenous formation of Nε-(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis. J. Hepatol. 2012, 56, 647–655. [Google Scholar] [CrossRef] [PubMed]
- Goldin, A.; Beckman, J.A.; Schmidt, A.M.; Creager, M.A. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation 2006, 114, 597–605. [Google Scholar] [CrossRef] [PubMed]
- Lohwasser, C.; Neureiter, D.; Popov, Y.; Bauer, M.; Schuppan, D. Role of the receptor for advanced glycation end products in hepatic fibrosis. World J. Gastroenterol. 2009, 15, 5789–5798. [Google Scholar] [CrossRef] [PubMed]
- Tanji, N.; Markowitz, G.S.; Fu, C.; Kislinger, T.; Taguchi, A.; Pischetsrieder, M.; Stern, D.; Schmidt, A.M.; D’Agati, V.D. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol. 2000, 11, 1656–1666. [Google Scholar] [CrossRef]
- Su, S.C.; Hung, Y.J.; Huang, C.L.; Shieh, Y.S.; Chien, C.Y.; Chiang, C.F.; Liu, J.S.; Lu, C.H.; Hsieh, C.H.; Lin, C.M.; et al. Cilostazol inhibits hyperglucose-induced vascular smooth muscle cell dysfunction by modulating the RAGE/ERK/NF-κB signaling pathways. J. Biomed. Sci. 2019, 26, 68. [Google Scholar] [CrossRef] [PubMed]
- Chiappalupi, S.; Sorci, G.; Vukasinovic, A.; Salvadori, L.; Sagheddu, R.; Coletti, D.; Renga, G.; Romani, L.; Donato, R.; Riuzzi, F. Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia. J. Cachexia Sarcopenia Muscle 2020, 11, 929–946. [Google Scholar] [CrossRef] [PubMed]
- Gao, X.; Zhang, H.; Schmidt, A.M.; Zhang, C. AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am. J. Physiol. Heart Circ. Physiol. 2008, 295, H491–H498. [Google Scholar] [CrossRef]
- Santilli, F.; Blardi, P.; Scapellato, C.; Bocchia, M.; Guazzi, G.; Terzuoli, L.; Tabucchi, A.; Silvietti, A.; Lucani, B.; Gioffrè, W.R. Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrome. Vasc. Pharmacol. 2015, 72, 16–24. [Google Scholar] [CrossRef]
Linear Regression Equation | Correlation Coefficient (R²) | Linear Range (μg/g) | LOD (μg/g) | LOQ (μg/g) |
---|---|---|---|---|
y = 8321x − 7022 | 0.9995 | 1.56–100.00 | 0.60 | 1.81 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lee, J.-A.; Gu, M.J.; Lee, Y.R.; Kim, Y.; Choi, I.; Kim, D.; Ha, S.K. Lindera obtusiloba Blume Alleviates Non-Alcoholic Fatty Liver Disease Promoted by Nε-(carboxymethyl)lysine. Nutrients 2024, 16, 2330. https://doi.org/10.3390/nu16142330
Lee J-A, Gu MJ, Lee YR, Kim Y, Choi I, Kim D, Ha SK. Lindera obtusiloba Blume Alleviates Non-Alcoholic Fatty Liver Disease Promoted by Nε-(carboxymethyl)lysine. Nutrients. 2024; 16(14):2330. https://doi.org/10.3390/nu16142330
Chicago/Turabian StyleLee, Jin-Ah, Min Ji Gu, Yu Ra Lee, Yoonsook Kim, Inwook Choi, Donghwan Kim, and Sang Keun Ha. 2024. "Lindera obtusiloba Blume Alleviates Non-Alcoholic Fatty Liver Disease Promoted by Nε-(carboxymethyl)lysine" Nutrients 16, no. 14: 2330. https://doi.org/10.3390/nu16142330